MEP43208A - Epitopna vakcina beta-amiloidne-analogne-t-ćelije - Google Patents

Epitopna vakcina beta-amiloidne-analogne-t-ćelije

Info

Publication number: MEP43208A
Authority: ME; Montenegro
Prior art keywords: amyloid; methods; app; analogs; vaccination
Prior art date: 2001-08-20

Application number

MEP-432/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Peter Birk Rasmussen

Martin Roland Jensen

Klaus Gregorius Nielsen

Peter Koefoed

Florence Dal Degan

Original Assignee

Pharmexa As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-20

Filing date

2002-08-20

Publication date

2011-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP43208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-20 Application filed by Pharmexa As filed Critical Pharmexa As

2011-02-10 Publication of MEP43208A publication Critical patent/MEP43208A/xx

Links

229960005486 vaccine Drugs 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 5
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
238000002255 vaccination Methods 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
238000002649 immunization Methods 0.000 abstract 2
230000003053 immunization Effects 0.000 abstract 2
150000007523 nucleic acids Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
230000007082 Aβ accumulation Effects 0.000 abstract 1
230000003942 amyloidogenic effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Environmental Sciences (AREA)
Zoology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Toxicology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hematology (AREA)

MEP-432/08A 2001-08-20 2002-08-20 Epitopna vakcina beta-amiloidne-analogne-t-ćelije MEP43208A (bs)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA200101231		2001-08-20
US33754301P	2001-10-22	2001-10-22
US37302702P	2002-04-16	2002-04-16
DKPA200200558		2002-04-16
PCT/DK2002/000547 WO2003015812A2 (en)	2001-08-20	2002-08-20	Beta-amyloid-analogue-t-cell epitop vaccine
YU13304A RS51699B (sr)	2001-08-20	2002-08-20	Beta-amiloid-analog-t-ćelijski-epitop vakcina

Publications (1)

Publication Number	Publication Date
MEP43208A true MEP43208A (bs)	2011-02-10

Family

ID=32870659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-432/08A MEP43208A (bs)	2001-08-20	2002-08-20	Epitopna vakcina beta-amiloidne-analogne-t-ćelije

Country Status (29)

Country	Link
US (3)	US20030157117A1 (pl)
EP (3)	EP1685847A1 (pl)
JP (2)	JP2004538332A (pl)
KR (3)	KR101057488B1 (pl)
CN (1)	CN101675992B (pl)
AR (1)	AR036270A1 (pl)
AT (1)	ATE334698T1 (pl)
AU (3)	AU2002325199B2 (pl)
BR (1)	BR0212047A (pl)
CA (1)	CA2457140C (pl)
CO (1)	CO5560581A2 (pl)
CY (1)	CY1105737T1 (pl)
DE (1)	DE60213615T3 (pl)
DK (1)	DK1420815T3 (pl)
EA (2)	EA011610B1 (pl)
ES (1)	ES2269749T5 (pl)
HR (2)	HRP20040218A2 (pl)
HU (1)	HUP0400669A3 (pl)
IL (2)	IL159964A0 (pl)
IS (1)	IS7133A (pl)
ME (1)	MEP43208A (pl)
MX (1)	MXPA04001467A (pl)
MY (1)	MY144532A (pl)
NZ (2)	NZ530940A (pl)
PL (1)	PL215125B1 (pl)
PT (1)	PT1420815E (pl)
RS (1)	RS51699B (pl)
SI (1)	SI1420815T1 (pl)
WO (1)	WO2003015812A2 (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5025871B2 (ja) *	2000-02-21	2012-09-12	エイチ．リュンドベックエイ／エス	アミロイドの新規なダウン−レギュレート方法
AU783144B2 (en) *	2000-02-21	2005-09-29	H. Lundbeck A/S	Novel method for down-regulation of amyloid
US7264810B2 (en)	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
US8697082B2 (en) *	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) *	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) *	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) *	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) *	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
KR100546066B1 (ko) *	2003-03-21	2006-01-26	한국생명공학연구원	베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20070184023A1 (en) *	2003-10-30	2007-08-09	Pharmexa A/S	Method for down-regulation of vegf
WO2005047860A2 (en)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Antibodies to alpha-synuclein
EP1711208A2 (en) *	2004-01-28	2006-10-18	Curix APS	Conjugates of amyloid proteins as vaccines for amyloid-related diseases
KR100639397B1 (ko) *	2004-03-18	2006-10-26	(주)에스제이바이오메드	항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
GB0424563D0 (en) *	2004-11-05	2004-12-08	Novartis Ag	Organic compounds
EP1879613B1 (en) *	2005-05-05	2011-11-30	Merck Sharp & Dohme Corp.	Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
JP5097695B2 (ja)	2006-02-22	2012-12-12	株式会社林原	抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
US8188046B2 (en)	2006-10-16	2012-05-29	University Of South Florida	Amyloid beta peptides and methods of use
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2583978T3 (pl) *	2007-02-23	2016-07-29	Prothena Biosciences Ltd Co	Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8147833B2 (en) *	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
US7618944B2 (en)	2007-03-01	2009-11-17	Intezyne Technologies, Inc.	Encapsulated amyloid-beta peptides
WO2008124646A2 (en) *	2007-04-06	2008-10-16	The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services	Use of amyloid proteins as vaccine scaffolds
ES2655868T3 (es)	2007-04-20	2018-02-22	The Chemo-Sero-Therapeutic Research Institute	Método para aumentar la respuesta inmunitaria con un péptido
AU2009268808A1 (en) *	2008-07-08	2010-01-14	Merck Sharp & Dohme Corp.	Vaccine for the treatment of Alzheimer's disease
US8512709B2 (en) *	2008-10-16	2013-08-20	The Chemo-Sero-Therapeutic Research Institue	Modified amyloid β peptide
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
WO2012020124A1 (en)	2010-08-12	2012-02-16	Ac Immune S.A.	Vaccine engineering
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
JP6027011B2 (ja)	2010-10-26	2016-11-16	エーシーイミューンソシエテアノニム	疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US20120328605A1 (en) *	2010-10-27	2012-12-27	Daniel Larocque	Compositions and uses
EP2887955B1 (en) *	2012-08-21	2020-08-19	Institute for Molecular Medicine, Inc.	Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US10195257B2 (en)	2013-07-28	2019-02-05	Qantu Therapeutics, Inc.	Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
US20160220649A1 (en) *	2013-09-13	2016-08-04	Fundación Pública Andaluza Progreso Y Salud	Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases
EP3116893B1 (en) *	2014-03-11	2019-08-28	Jacques Fantini	A chimeric peptide that interacts with cell membrane gangliosides
US10441649B2 (en) *	2015-02-02	2019-10-15	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
CN104880441B (zh) *	2015-05-14	2017-12-22	上海皓拓生物技术有限公司	β‑分泌酶特异性抑制剂的筛选方法及其筛选系统
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
AU2017350473A1 (en)	2016-10-28	2019-04-18	H. Lundbeck A/S	Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
WO2018078042A1 (en)	2016-10-28	2018-05-03	H. Lundbeck A/S	Combination treatments comprising administration of imidazopyrazinones
WO2018132768A1 (en) *	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
CN108187038B (zh) *	2017-05-25	2020-05-01	成都安特金生物技术有限公司	一种狂犬病结合疫苗
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
EP3723807B1 (en)	2017-12-14	2021-10-20	H. Lundbeck A/S	Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
WO2019121840A1 (en)	2017-12-20	2019-06-27	H. Lundbeck A/S	Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN112165956A (zh) *	2018-04-10	2021-01-01	Ac免疫有限公司	抗Aβ治疗性疫苗
AU2019253193B2 (en)	2018-04-10	2026-02-05	Ac Immune Sa	Anti-abeta therapeutic vaccines
WO2020210843A2 (en)	2019-04-12	2020-10-15	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
EP3952913A4 (en) *	2019-04-12	2023-05-10	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
GB202008250D0 (en) *	2020-06-02	2020-07-15	Emergex Vaccines Holding Ltd	Diagnosis, prevention and treatment of coronavirus infection
JP2024504194A (ja) *	2021-01-29	2024-01-30	エランコアニマルヘルスゲー・エム・ベー・ハー	自己寛容を破壊するためのワクチン組成物
WO2023159970A1 (zh) *	2022-02-28	2023-08-31	安域生物科技杭州有限公司	基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN117700525B (zh) *	2024-02-05	2024-06-18	上海良润生物医药科技有限公司	一种多肽改造体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en)	1981-09-04	1986-06-24	The Regents Of The University Of California	Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja)	1982-08-30	1984-03-02	Musashi Eng Kk	紙葉判別方法
US4599231A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en)	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en)	1985-05-01	1986-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5223482A (en) *	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5278056A (en) *	1988-02-05	1994-01-11	The Trustees Of Columbia University In The City Of New York	Retroviral packaging cell lines and process of using same
US5192688A (en) *	1988-08-15	1993-03-09	Switzer Iii Robert C	Histological analysis method
US5753624A (en) *	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US5200339A (en) *	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
US5780587A (en) *	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5780036A (en) *	1991-08-26	1998-07-14	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
ES2204900T3 (es)	1992-02-11	2004-05-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Estructura inmuinogena de doble vector.
AU678152B2 (en)	1992-03-27	1997-05-22	Whitehead Institute For Biomedical Research	Non-infectious HIV particles and uses therefor
US5851787A (en)	1992-04-20	1998-12-22	The General Hospital Corporation	Nucleic acid encoding amyloid precursor-like protein and uses thereof
WO1993023076A1 (en)	1992-05-20	1993-11-25	The Johns-Hopkins University	Alternative receptor therapy
DK100592D0 (da)	1992-08-10	1992-08-10	Mouritsen & Elsner Aps	Metode til kemisk kobling paa faste faser
US5958883A (en) *	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
US5747323A (en) *	1992-12-31	1998-05-05	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Retroviral vectors comprising a VL30-derived psi region
DK96493D0 (da)	1993-08-26	1993-08-26	Mouritsen Og Elsner Aps	Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU707083B2 (en)	1993-08-26	1999-07-01	Bavarian Nordic Inc.	Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DE69435171D1 (de)	1993-09-14	2009-01-08	Pharmexa Inc	Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPM411994A0 (en)	1994-02-25	1994-03-24	Deakin Research Limited	Epitopes
US5709995A (en) *	1994-03-17	1998-01-20	The Scripps Research Institute	Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5573916A (en) *	1994-05-19	1996-11-12	Coretech, Inc.	Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
IL115743A0 (en)	1994-10-28	1996-01-19	American Nat Red Cross	A mammal with cells containing a transgene and its production
US5589154A (en) *	1994-11-22	1996-12-31	Rutgers, The State University Of New Jersey	Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5854204A (en) *	1995-03-14	1998-12-29	Praecis Pharmaceuticals, Inc.	Aβ peptides that modulate β-amyloid aggregation
PT832093E (pt)	1995-06-07	2006-12-29	Sanofi Pasteur Inc	Expressão de lipoproteínas
US5874469A (en)	1996-01-05	1999-02-23	Alcon Laboratories, Inc.	Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5985581A (en)	1996-07-25	1999-11-16	The Mclean Hospital Corporation	Use of presenilin-1 for diagnosis of alzheimers disease
AUPO390396A0 (en)	1996-11-29	1996-12-19	Csl Limited	Novel promiscuous T helper cell epitopes
AU724294B2 (en)	1997-01-22	2000-09-14	Eisai Inc.	Microparticles for delivery of nucleic acid
AU1388899A (en)	1997-11-11	1999-05-31	Board Of Regents Of The University Of Oklahoma, The	An alzheimer-related, endothelium-derived toxic factor and methods for its use
US6913745B1 (en) *	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6761888B1 (en) *	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) *	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20040062802A1 (en) *	1998-04-02	2004-04-01	Hermelin Victor M.	Maximizing effectiveness of substances used to improve health and well being
NO314086B1 (no) *	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
JP2002521651A (ja)	1998-07-21	2002-07-16	ファーメクサエイ／エス	活性ポリヒドロキシポリマーでの固体表面の被覆
HUP0103578A3 (en) *	1998-09-15	2005-11-28	Pharmexa As	Method for down-regulating osteoprotegerin ligand activity
SK4272001A3 (en) *	1998-10-05	2003-02-04	Pharmexa As	Methods for therapeutic vaccination
GB2361948B (en) †	1998-11-06	2003-04-16	Baker Hughes Inc	Drilling fluid systems with improved fluid loss properties
WO2000040741A2 (en)	1999-01-07	2000-07-13	The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health	Lentivirus vector system
PT1187629E (pt) *	1999-04-19	2005-02-28	Glaxosmithkline Biolog Sa	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6787637B1 (en) *	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
PE20010212A1 (es)	1999-06-01	2001-02-22	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
MXPA02005576A (es)	1999-11-29	2002-12-13	Neurochem Inc	Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
EP1237930B1 (en) *	1999-12-08	2006-11-08	Intellect Neurosciences, Inc.	Chimeric amyloid beta peptides
JP5025871B2 (ja)	2000-02-21	2012-09-12	エイチ．リュンドベックエイ／エス	アミロイドの新規なダウン−レギュレート方法
AU783144B2 (en) *	2000-02-21	2005-09-29	H. Lundbeck A/S	Novel method for down-regulation of amyloid
GB0004530D0 (en)	2000-02-25	2000-04-19	Univ Nottingham	Adjuvants
AU2001274873B2 (en) *	2000-05-22	2006-10-05	New York University	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
IL155690A0 (en)	2000-11-10	2003-11-23	Wyeth Corp	Adjuvant combination formulations
US7097837B2 (en) *	2001-02-19	2006-08-29	Pharmexa A/S	Synthetic vaccine agents
JP2002273199A (ja) *	2001-03-15	2002-09-24	Idemitsu Petrochem Co Ltd	ガス状流体の抜き出し方法
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
US20030185845A1 (en) *	2001-11-16	2003-10-02	Steen Klysner	Novel immunogenic mimetics of multimer proteins
WO2003059379A2 (en)	2002-01-17	2003-07-24	Pharmexa A/S	Immunogenic carcinoembryonic antigen (cea)
WO2003075951A2 (en) *	2002-03-11	2003-09-18	Pharmexa A/S	Novel application of vaccination against tnf-alpha
US20040091945A1 (en) *	2002-07-17	2004-05-13	Cheryl Fitzer-Attas	Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease

2002
- 2002-08-13 MY MYPI20023002A patent/MY144532A/en unknown
- 2002-08-20 HR HR20040218A patent/HRP20040218A2/hr not_active Application Discontinuation
- 2002-08-20 EP EP06000288A patent/EP1685847A1/en not_active Ceased
- 2002-08-20 NZ NZ530940A patent/NZ530940A/en unknown
- 2002-08-20 MX MXPA04001467A patent/MXPA04001467A/es active IP Right Grant
- 2002-08-20 AT AT02758181T patent/ATE334698T1/de active
- 2002-08-20 AR ARP020103113A patent/AR036270A1/es active IP Right Grant
- 2002-08-20 CA CA2457140A patent/CA2457140C/en not_active Expired - Fee Related
- 2002-08-20 WO PCT/DK2002/000547 patent/WO2003015812A2/en not_active Ceased
- 2002-08-20 RS YU13304A patent/RS51699B/sr unknown
- 2002-08-20 KR KR1020097013183A patent/KR101057488B1/ko not_active Expired - Fee Related
- 2002-08-20 BR BR0212047-0A patent/BR0212047A/pt not_active IP Right Cessation
- 2002-08-20 EP EP02758181.8A patent/EP1420815B2/en not_active Expired - Lifetime
- 2002-08-20 IL IL15996402A patent/IL159964A0/xx unknown
- 2002-08-20 EP EP17194894.6A patent/EP3299029A1/en not_active Withdrawn
- 2002-08-20 JP JP2003520770A patent/JP2004538332A/ja active Pending
- 2002-08-20 HU HU0400669A patent/HUP0400669A3/hu not_active Application Discontinuation
- 2002-08-20 PL PL369099A patent/PL215125B1/pl unknown
- 2002-08-20 CN CN200910204496.3A patent/CN101675992B/zh not_active Expired - Fee Related
- 2002-08-20 SI SI200230418T patent/SI1420815T1/sl unknown
- 2002-08-20 NZ NZ547224A patent/NZ547224A/en not_active IP Right Cessation
- 2002-08-20 HR HRP20120283AA patent/HRP20120283A2/hr not_active Application Discontinuation
- 2002-08-20 EA EA200600974A patent/EA011610B1/ru not_active IP Right Cessation
- 2002-08-20 DK DK02758181T patent/DK1420815T3/da active
- 2002-08-20 ES ES02758181.8T patent/ES2269749T5/es not_active Expired - Lifetime
- 2002-08-20 PT PT02758181T patent/PT1420815E/pt unknown
- 2002-08-20 US US10/223,809 patent/US20030157117A1/en not_active Abandoned
- 2002-08-20 AU AU2002325199A patent/AU2002325199B2/en not_active Ceased
- 2002-08-20 KR KR10-2004-7002557A patent/KR20040044465A/ko not_active Ceased
- 2002-08-20 ME MEP-432/08A patent/MEP43208A/xx unknown
- 2002-08-20 EA EA200400332A patent/EA007533B1/ru not_active IP Right Cessation
- 2002-08-20 KR KR1020107015762A patent/KR20100086520A/ko not_active Ceased
- 2002-08-20 DE DE60213615.6T patent/DE60213615T3/de not_active Expired - Lifetime
2004
- 2004-01-29 IS IS7133A patent/IS7133A/is unknown
- 2004-02-20 US US10/783,317 patent/US20050163744A1/en not_active Abandoned
- 2004-02-23 CO CO04015504A patent/CO5560581A2/es not_active Application Discontinuation
2006
- 2006-10-26 CY CY20061101544T patent/CY1105737T1/el unknown
2007
- 2007-12-18 AU AU2007249087A patent/AU2007249087B2/en not_active Expired - Fee Related
- 2007-12-31 IL IL188506A patent/IL188506A/en not_active IP Right Cessation
2008
- 2008-12-19 US US12/339,841 patent/US8871212B2/en not_active Expired - Fee Related
2009
- 2009-06-12 JP JP2009141187A patent/JP5114455B2/ja not_active Expired - Fee Related
2010
- 2010-08-16 AU AU2010212381A patent/AU2010212381B2/en not_active Ceased

Also Published As

Publication number	Publication date
CA2457140A1 (en)	2004-02-27
KR101057488B1 (ko)	2011-08-19
WO2003015812A3 (en)	2004-03-25
AU2007249087B2 (en)	2010-05-20
EA007533B1 (ru)	2006-10-27
IS7133A (is)	2004-01-29
CN101675992B (zh)	2014-05-21
CY1105737T1 (el)	2010-12-22
AU2010212381B2 (en)	2012-01-19
DE60213615T3 (de)	2017-11-23
IL159964A0 (en)	2004-06-20
CO5560581A2 (es)	2005-09-30
HRP20040218A2 (en)	2004-08-31
KR20090074830A (ko)	2009-07-07
KR20040044465A (ko)	2004-05-28
HUP0400669A2 (hu)	2005-01-28
NZ530940A (en)	2007-11-30
EP1685847A1 (en)	2006-08-02
ES2269749T5 (es)	2017-12-04
AU2007249087A1 (en)	2008-01-10
EP1420815B1 (en)	2006-08-02
KR20100086520A (ko)	2010-07-30
PL369099A1 (pl)	2005-04-18
US8871212B2 (en)	2014-10-28
HRP20120283A2 (hr)	2012-06-30
CN101675992A (zh)	2010-03-24
PL215125B1 (pl)	2013-10-31
US20050163744A1 (en)	2005-07-28
SI1420815T1 (sl)	2006-12-31
ES2269749T3 (es)	2007-04-01
PT1420815E (pt)	2006-12-29
DE60213615D1 (de)	2006-09-14
HUP0400669A3 (en)	2011-07-28
AU2002325199B2 (en)	2007-09-20
YU13304A (sh)	2006-08-17
JP2004538332A (ja)	2004-12-24
NZ547224A (en)	2008-06-30
IL188506A (en)	2017-08-31
EA200600974A1 (ru)	2006-10-27
US20100047262A1 (en)	2010-02-25
CA2457140C (en)	2014-08-05
US20030157117A1 (en)	2003-08-21
MXPA04001467A (es)	2005-02-17
EP1420815B2 (en)	2017-08-09
JP5114455B2 (ja)	2013-01-09
EP3299029A1 (en)	2018-03-28
EA200400332A1 (ru)	2004-08-26
WO2003015812A2 (en)	2003-02-27
AR036270A1 (es)	2004-08-25
ATE334698T1 (de)	2006-08-15
HK1064934A1 (en)	2005-02-08
BR0212047A (pt)	2004-08-17
EP1420815A2 (en)	2004-05-26
RS51699B (sr)	2011-10-31
DE60213615T2 (de)	2007-08-09
MY144532A (en)	2011-09-30
EA011610B1 (ru)	2009-04-28
JP2009280582A (ja)	2009-12-03
AU2010212381A1 (en)	2010-09-09
DK1420815T3 (da)	2006-12-04
IL188506A0 (en)	2008-04-13

Publication	Publication Date	Title
MEP43208A (bs)	2011-02-10	Epitopna vakcina beta-amiloidne-analogne-t-ćelije
MEP30408A (en)	2010-10-10	Novel method for down-regulation of amyloid
MXPA02007796A (es)	2003-12-08	Metodo novedoso para la disminucion de cuerpos amiloides.
AR032597A1 (es)	2003-11-19	Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
AU2018298422A1 (en)	2019-12-19	Novel nucleic acid molecules
UA130113C2 (uk)	2025-11-19	Мутеїн інтерлейкіну-21
BR112022016550A2 (pt)	2022-11-16	Proteínas de ligação a flt3 e métodos de uso
BR9907691A (pt)	2000-11-14	Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
NO20054608L (no)	2005-12-07	Influensavirusvaksine
SE0202110D0 (sv)	2002-07-05	Iscom preparation and use thereof
MX2022013963A (es)	2023-02-22	Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
DE60020570D1 (de)	2005-07-07	Rotavirus impfstoffformulierungen
EA201391200A1 (ru)	2014-05-30	Способы и композиции для вакцинации от staphylococcus aureus
AR023535A1 (es)	2002-09-04	Nuevas composiciones.
BR0211761A (pt)	2007-01-09	depsipeptìdeos e processos para preparar os mesmos
ATE507286T1 (de)	2011-05-15	Immunisierung von fischen gegen virusinfektion
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE
EA202191735A1 (ru)	2021-11-24	Варианты альфа-галактозидазы человека
NO20040431L (no)	2004-04-16	Ny fremgangsmate for nedregulering av amyloid
SE9903534D0 (sv)	1999-09-30	Vaccin
DE60126490D1 (de)	2007-03-22	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
AR248047A1 (es)	1995-05-31	Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.
YU87201A (sh)	2004-09-03	Postupak za nishodnu regulaciju gdf-8 aktivnosti
CU23009A1 (es)	2004-12-17	Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos